Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization

Low-density lipoprotein (LDL) aggregation is nowadays considered a therapeutic target in atherosclerosis. DP3, the retro-enantio version of the sequence Gly1127-Cys1140 of LRP1, efficiently inhibits LDL aggregation and foam cell in vitro formation. Here, we investigate whether DP3 modulates atherosc...

Descripción completa

Detalles Bibliográficos
Autores: Benitez-Amaro, Aleyda, García, Eduardo, La Chica Lhoëst, Maria Teresa, Martínez, A., Borràs, Carla, Tondo, Mireia, Cespédes, Virtudes M., Caruana, P., Pepe, A., Bochicchio, B., Cenarro, Ana, Civeira, Fernando, Prades, Roger, Escolà-Gil, Joan Carles, Llorente-Cortés, Vicenta
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/420699
Acceso en línea:http://hdl.handle.net/10261/420699
https://api.elsevier.com/content/abstract/scopus_id/85209237336
Access Level:acceso abierto
Palabra clave:ApoB100 conformation
Atherosclerosis
LDL aggregation
LRP1-Based peptides
Therapeutic peptides
Descripción
Sumario:Low-density lipoprotein (LDL) aggregation is nowadays considered a therapeutic target in atherosclerosis. DP3, the retro-enantio version of the sequence Gly1127-Cys1140 of LRP1, efficiently inhibits LDL aggregation and foam cell in vitro formation. Here, we investigate whether DP3 modulates atherosclerosis in a humanized ApoB100, LDL receptor (LDLR) knockout mice (Ldlr-/-hApoB100 Tg) and determine the potential LDL-related underlying mechanisms.

Similares en LA Referencia